Drug Trial Radar · NCT06343792
Safety, PK, PD, Dosing, and Efficacy of RLS-0071for the Treatment of Hospitalized Patients With Steroid-Refractory Acute Graft-versus-Host Disease
Last checked: Nov 19, 2026Latest source record: Nov 24, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
66
Planned (sponsor's estimate)
Start
Aug 31, 2024
Primary completion
Dec 2026
Study completion Dec 2026
Sponsor
- Lead sponsor
- ReAlta Life Sciences, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- CTI Clinical Trial and Consulting Services
- First posted
- Apr 3, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a Open Label Prospective Dose-Ranging Escalation and Expansion Trial to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Dosing, and Efficacy of RLS-0071 for the secondary treatment of acute Graft-versus-Host Disease (aGvHD) in hospitalized patients who are steroid-refractory.
Conditions
- Steroid Refractory GVHD
Interventions
RLS-0071Drug
RLS-0071 will be administered for 7 or 14 days according to the assigned dose group.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with treatment-related adverse events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs)Time frame: Day 1 to Day 180
- Overall Response Rate (ORR) of RLS-0071Time frame: Day 1 to Day 28
Locations
11 sites in 3 countries. Site status is shown where the registry gives one.
Site 1091
Duarte, California · Active not recruiting
Site 1343
Los Angeles, California · Active not recruiting
Site 1318
Atlanta, Georgia · Active not recruiting
Site 1068
St Louis, Missouri · Active not recruiting
Site 1100
Cincinnati, Ohio · Active not recruiting
Site 1382
Columbus, Ohio · Active not recruiting
Site 3242
Freiburg im Breisgau, Germany · Recruiting
Site 3360
Madrid, Spain · Recruiting
Site 3227
Salamanca, Spain · Recruiting
Site 3101
Seville, Spain · Recruiting
Site 3101
Seville, SE, Spain · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.